ArticlePhysiological reports2025
Distinct lung functional, histological and cell senescence signatures in the single and repetitive bleomycin mouse models of idiopathic pulmonary fibrosis.
Article in Physiological reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Repeated instillations of bleomycin in male mice induce a perivascular remodeling at distance of fibrotic areas in the context of progressive pulmonary fibrosis.Animal models and experimental medicine · 2026Article
- Nintedanib Lacks Efficacy in a Spirometry-Confirmed and Bleomycin-Induced Mouse Model of Idiopathic Pulmonary Fibrosis.Basic & clinical pharmacology & toxicology · 2026Article
- The chemokine network in lupus nephritis: pathogenesis, targeted therapies, and future directions.Frontiers in pharmacology · 2026Review
- Nanocarrier-Enabled siRNA Therapy for Pulmonary Fibrosis: Pharmacological Rationale, Delivery Barriers, and Translational Opportunities.International journal of nanomedicine · 2026Review
- Distinct lung functional, histological and cell senescence signatures in the single and repetitive bleomycin mouse models of idiopathic pulmonary fibrosis.Physiological reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
This study aimed to comprehensively compare the lung disease phenotypes between single-dose and repetitive-dose bleomycin (BLEO)-induced mouse models of idiopathic pulmonary fibrosis (IPF). Male C57BL/6JRj mice were randomized and stratified to treatment according to body weight. Mice received either a single intratracheal instillation of BLEO (n = 14) or a repetitive regimen involving bi-weekly BLEO instillations over 4 weeks (n = 30). Two weeks after the last BLEO dose, mice were assigned as baseline (n = 13) or repetitive BLEO-IPF mice (terminated 8 weeks after baseline, n = 17). Saline-treated mice served as healthy controls (n = 10 per model). The repetitive BLEO-IPF mouse demonstrated sustained features of lung fibrosis, including persistent increases in lung hydroxyproline content, Ashcroft scores, and quantitative collagen levels 8 weeks after baseline. Histological analysis revealed ongoing pulmonary inflammation and accumulation of senescent myofibroblasts. Lung functional impairment was selective but persistent, with FEV0.1 being significantly reduced on study week 8. Lung transcriptome signatures in repetitive BLEO-IPF mice were comparable to those reported in end-stage IPF patients, albeit attenuated 8 weeks after baseline, suggesting initiation of reparative processes. The repetitive BLEO-IPF mouse model recapitulates histological features of progressive lung fibrosis with an evolving cellular senescence phenotype, offering a relevant preclinical platform for studying IPF pathophysiology and evaluating long-term effects of antifibrotic and senescence-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.